Oxford Biomedica, Santen enter retinal disease R&D alliance

pharmatimes | June 26, 2019

Oxford Biomedica, Santen enter retinal disease R&D alliance
Oxford Biomedica and Santen have announced plans to enter into a research and development collaboration and option and licence agreement for development of gene therapy vectors for inherited retinal disease. The aim of the collaboration is to generate pre-clinical proof of concept to treat an inherited retinal disease with lentiviral vectors developed and manufactured by Oxford Biomedica, and includes a licence to use the company’s LentiVector platform. John Dawson, chief executive officer of Oxford Biomedica, said that the company is “delighted to have formed our first collaboration in Japan. Santen is a leading, multi-national ophthalmology company developing an innovative gene therapy product for the treatment of a significant inherited retinal disease affecting patients with few or no therapy options. Inherited retinal diseases are ideal candidates for gene therapy because many of the responsible genetic mutations have already been identified. In addition, the eye is a readily accessible organ conducive to direct delivery of gene therapy vectors to the diseased tissue. A key advantage with lentiviral vectors is their ability to deliver large therapeutic genes, which is technically challenging with other vector systems.

Spotlight

Vaccines trick the body into building immunity against infectious diseases without causing the actual disease. Vaccines achieve this by introducing a dead or weakened version of the disease-causing germ (bacteria or virus) to the body’s immune system. In some cases, inactivated toxins (poisonous substances) produced by the germ are used in the vaccine to develop immunity (for example, diphtheria and tetanus vaccines).

Spotlight

Vaccines trick the body into building immunity against infectious diseases without causing the actual disease. Vaccines achieve this by introducing a dead or weakened version of the disease-causing germ (bacteria or virus) to the body’s immune system. In some cases, inactivated toxins (poisonous substances) produced by the germ are used in the vaccine to develop immunity (for example, diphtheria and tetanus vaccines).

Related News

Fixx Pharmaceuticals Wants to Dominate Hemophilia Market With Gene Editing

Prnewswire | August 28, 2020

Fixx Pharmaceuticals Inc. is pleased to announce the launch of its biotechnology business operations in Las Vegas, Nevada and San Francisco, California. The company is focused on developing a cure for Hemophilia through the use of CRISPR gene editing. There are currently 20,000 people in the U.S. who suffer from hemophilia and 400,000 globally. "We are looking to commercialize a product as soon as possible," says Jesse John Francis Clark, founder of Fixx. "We are going to develop a product that is more cost-effective for payers. We're looking to keep it under $2 million per patient," he said, saying that the overall cost of care of hemophilia patients will decrease. "If we are successful in developing a commercialized product, we are looking at upwards of $40 billion in sales from the U.S. market alone. I think our investors will be happy with that," says Clark.

Read More

PHARMA TECH

CareRx Applauds Ontario Ministry of Health's Pause of Planned Fee Changes

CareRx | January 18, 2021

CareRx Corporation ("CareRx" or the "Company") (TSX: CRRX), Canada's leading provider of specialty pharmacy services to seniors, is pleased that the Ontario Ministry of Health has announced that it will pause for one year previously scheduled changes to long-term care pharmacy funding, which were scheduled to go into effect on April 1, 2021. Under certain amendments to the Ontario Drug Benefit Act that came into effect on January 1, 2020, the reimbursement model for long-term care pharmacies in Ontario was changed from a fee-for-service model to a fee-per-bed capitation model under which pharmacies receive a fixed professional fee for all pharmacy services provided to residents in long-term care homes. The fee for 2020, which was prescribed at $1,500, was scheduled to decline to $1,400 per bed serviced on April 1, 2021. The step-down in capitation has now been paused until April 1, 2022. "Long-term care homes and their staff have faced unprecedented challenges during COVID-19," said David Murphy, President and Chief Executive Officer of CareRx. "This pause will ensure that pharmacies like CareRx can continue to deliver the same exceptional partnership and service offering to long-term care homes and help alleviate the burden COVID-19 has placed on home staff. We want to thank Minister Elliott, Minister Fullerton and the Ontario Government for their ongoing dialogue and commitment to protecting the wellbeing of residents in long-term care." About CareRx Corporation CareRx is Canada's leading provider of specialty pharmacy services to seniors. We serve approximately 50,000 residents in over 900 seniors and other communities (long-term care homes, retirement homes, assisted living facilities, and group homes). We are a national organization with a large network of pharmacy fulfillment centres strategically located across the country. This allows us to deliver medications in a timely and cost-effective manner and quickly respond to routine changes in medication management. We use best-in-class technology that automates the preparation and verification of multi-dose compliance packaging of medication, providing the highest levels of safety and adherence for individuals with complex medication regimes. We take an active role in working with our home operator partners to promote resident health, staff education, and medication system quality and efficiency.

Read More

RESEARCH

Moderna and Medison Pharma Collaborate to Commercialize Moderna's COVID-19 Vaccine in Central Eastern Europe and Israel

Moderna | June 08, 2021

Moderna, Inc., a biotechnology company that pioneered messenger RNA (mRNA) therapeutics and vaccines, and Medison Pharma, a leading commercial partner for highly innovative therapies in international markets, announced today a new agreement to commercialize the Moderna COVID-19 Vaccine in Central Eastern Europe and Israel. Poland, Czech Republic, Romania, Hungary, Bulgaria, Slovenia, Slovakia, Croatia, Estonia, Latvia, Lithuania, Serbia, Ukraine, Moldova, Albania, Bosnia, and Herzegovina, Kosovo, North Macedonia, Montenegro, and Israel are among the nations included by the pact. "We are excited to work with Moderna in 20 markets, covering over 175 million people across the whole Central Eastern Europe region and in Israel," stated Meir Jakobsohn, Medison Pharma's Founder and CEO. "With Moderna's ground-breaking mRNA vaccine and Medison's international commercialization platform for highly innovative treatments, our collaboration is a perfect fit." "We value this new collaboration with Medison Pharma to ensure the successful launch of our mRNA COVID-19 vaccine," stated Corinne Le Goff, Pharm.D., M.B.A., Chief Commercial Officer of Moderna. "By delivering our vaccines in collaboration with our partners, we stay consistent in our commitment to fighting the pandemic." About Medison Pharma Medison is a global pharmaceutical company that focuses on commercializing highly innovative therapies in international markets. Medison offers a full range of integrated services for companies looking to establish a presence in international markets, drawing on a 25-year track record and collaborations with major biotech companies. Medison also has a corporate venture arm with a dedicated research and evaluation team with significant scientific and commercial expertise. About Moderna Moderna has evolved from a science research-stage company advancing programs in the field of messenger RNA (mRNA) to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across six modalities, a broad intellectual property portfolio in areas such as mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant. Moderna maintains alliances with a diverse range of domestic & global government and commercial collaborators, allowing for the pursuit of both ground-breaking science and rapid manufacturing scale.

Read More